Cardiac allograft vasculopathy--a changing perspective

M E Russell1

  • 1Harvard School of Public Health, 665 Huntington Avenue, Boston, MA 02215, USA.

Zeitschrift Fur Kardiologie
|January 11, 2001
PubMed

Insights

Cardiac allograft vasculopathy (CAV) is a complex condition involving multiple factors. Future therapies aim to modify both the donor organ and the recipient

Area of Science:

  • Cardiology
  • Immunology
  • Transplantation Science

Background:

  • Cardiac allograft vasculopathy (CAV) is a significant long-term complication after heart transplantation.
  • It is characterized by diffuse intimal thickening and graft dysfunction.

Purpose of the Study:

  • To elucidate the multifactorial nature of Cardiac allograft vasculopathy (CAV).
  • To identify key therapeutic targets for preventing and treating CAV.

Main Methods:

  • Review of recent clinical and basic studies on CAV.
  • Analysis of contributing factors including fibrosis, arteritis, and atheroma.

Main Results:

  • CAV is regulated by interacting forces at different stages of the disease process.
  • Three primary forms of vasculopathy—fibrosis, arteritis, and atheroma—contribute to graft vascular disease.

Conclusions:

  • Current CAV therapies must address both alloantigen-dependent and independent factors.
  • Future strategies should involve donor manipulation (reducing antigenicity/ischemia) and recipient manipulation (donor-specific immune response modulation).